Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

PURPOSE Currently available clinical and molecular prognostic factors provide an imperfect assessment of prognosis for patients with epithelial ovarian cancer (EOC). In this study, we investigated whether tumor transcription profiling could be used as a prognostic tool in this disease. METHODS Tumor tissue from 68 patients was profiled with oligonucleotide microarrays. Samples were randomly split into training and validation sets. A three-step training procedure was used to discover a statistically significant Kaplan-Meier split in the training set. The resultant prognostic signature was then tested on an independent validation set for confirmation. RESULTS In the training set, a 115-gene signature referred to as the Ovarian Cancer Prognostic Profile (OCPP) was identified. When applied to the validation set, the OCPP distinguished between patients with unfavorable and favorable overall survival (median, 30 months v not yet reached, respectively; log-rank P = .004). The signature maintained independent prognostic value in multivariate analysis, controlling for other known prognostic factors such as age, stage, grade, and debulking status. The hazard ratio for death in the unfavorable OCPP group was 4.8 (P = .021 by Cox proportional hazards analysis). CONCLUSION The OCPP is an independent prognostic determinant of outcome in EOC. The use of gene profiling may ultimately permit identification of EOC patients appropriate for investigational treatment approaches, based on a low likelihood of achieving prolonged survival with standard first-line platinum-based therapy.

[1]  F. Kikkawa,et al.  Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells , 2004, Clinical & Experimental Metastasis.

[2]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  B. Modan,et al.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Thomas Waerner,et al.  Expression profiling of epithelial plasticity in tumor progression , 2003, Oncogene.

[5]  S. Rubin.  BRCA‐related ovarian carcinoma , 2003, Cancer.

[6]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[7]  A. Krüger,et al.  Clinical Relevance of the Plasminogen Activator Inhibitor Type1 – a Multifaceted Proteolytic Factor , 2001, Oncology Research and Treatment.

[8]  N. Auersperg,et al.  E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Ioannidis,et al.  Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment , 2003, The Lancet.

[10]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[11]  Andrea Califano,et al.  Analysis of Gene Expression Microarrays for Phenotype Classification , 2000, ISMB.

[12]  S. Cannistra,et al.  BAX protein expression and clinical outcome in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[14]  S. Cannistra.  Medical progress : cancer of the ovary , 1993 .

[15]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[16]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[17]  R. Nagle,et al.  N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. , 1999, The American journal of pathology.

[18]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[19]  Gustavo Stolovitzky,et al.  Genes@Work: an efficient algorithm for pattern discovery and multivariate feature selection in gene expression data , 2004, Bioinform..

[20]  Andrea Califano,et al.  SPLASH: structural pattern localization analysis by sequential histograms , 2000, Bioinform..

[21]  A. Hongo,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis. , 2001, International journal of oncology.

[22]  Andrea Califano,et al.  Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. , 2003, The Journal of clinical investigation.

[23]  David Ward,et al.  Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data , 2003, Bioinform..

[24]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[25]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[26]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[28]  M. Carcangiu,et al.  Plasminogen activator inhibitor‐1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients , 1998, International journal of cancer.

[29]  D. Charnock-Jones,et al.  Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma , 2003, British Journal of Cancer.

[30]  R. L. Baldwin,et al.  Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.

[31]  A. Hongo,et al.  Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. , 2001, Anticancer research.

[32]  Y. Terai,et al.  Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. , 2001, Gynecologic oncology.

[33]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[34]  Y. Tu,et al.  Gene Expression Dynamics during Germinal Center Transit in B Cells , 2003, Annals of the New York Academy of Sciences.

[35]  R. Kimmig,et al.  Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Wilander,et al.  Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. , 1993, Cancer research.

[37]  Saejoon Kim.  Protein ß-turn prediction using nearest-neighbor method , 2004, Bioinform..

[38]  Y. Jeng,et al.  Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. , 2004, Journal of biomedical science.

[39]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[40]  D. Chopin,et al.  Epithelial Cell Plasticity in Development and Tumor Progression , 2004, Cancer and Metastasis Reviews.

[41]  A. Ullrich,et al.  Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  I. Kohane,et al.  Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. , 2003, The Journal of thoracic and cardiovascular surgery.

[43]  Anne Vincent-Salomon,et al.  Epithelial–mesenchymal transition in breast cancer development , 2003 .

[44]  Andrea Califano,et al.  Transcriptional analysis of the B cell germinal center reaction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Höfler,et al.  Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc , 1999, British Journal of Cancer.

[47]  Y Tenjin,et al.  Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. , 2001, Human cell.

[48]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.